According to a story in thepharmaletter, in Business Monitor International’s fourth-quarter 2010 Pharmaceuticals & Healthcare Business Environment Ratings (BERs) report, Belgium (scoring 65.1/100) placed fifth in the Western Europe matrix, on a par with the UK and below Germany, Switzerland, France and Sweden. Encouragment of the use of generics is slowing market rates of growth.
This is just another data point that shows the advent of generics is having an impact on market size and growth in terms of revenues. Another factor increasing the pressure on revenues in addition to the patent cliffs, late stage failures in the pipeline, and increasing global competition.
Posted by Bruce Lehr September 18th 2010.